Cancer, An Overview of Eccrine Carcinoma


Article Author:
Hatem Kaseb


Article Editor:
Hani Babiker


Editors In Chief:
Stephen Leslie
Karim Hamawy


Managing Editors:
Avais Raja
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Khalid Alsayouri
Trevor Nezwek
Radia Jamil
Patrick Le
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Hassam Zulfiqar
Steve Bhimji
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Sarosh Vaqar
Mark Pellegrini
James Hughes
Beata Beatty
Nazia Sadiq
Hajira Basit
Phillip Hynes
Tehmina Warsi


Updated:
6/26/2019 12:22:02 PM

Introduction

Eccrine carcinoma (EC) is a rare carcinoma that originates from the eccrine sweat glands of the skin and accounts for less than 0.01% of diagnosed cutaneous malignancies.[1] Sweat gland tumors have traditionally subdivided into four broad groups: eccrine, apocrine, mixed origin (eccrine and apocrine) and other un-classifiable sweat gland tumors. Eccrine tumors further divide into benign and malignant. Benign entities include poroma, hidradenoma, spiradenoma, cylindroma, syringometaplasia, syringoma, syringofibroadenoma, and chondroid syringoma. Malignant eccrine carcinoma entities include porocarcinoma, hidradenocarcinoma, malignant spiradenoma carcinoma, malignant cylindroma, syringoid eccrine carcinoma, microcystic adnexal carcinoma, mucinous carcinoma, adenoid cystic carcinoma, and ductal papillary adenocarcinoma. Other un-classifiable sweat gland tumors include eccrine ductal carcinoma, basaloid eccrine carcinoma, clear cell eccrine carcinoma and non-specified sweat gland carcinomas.

Malignant sweat gland tumors are heterogeneous neoplasms of different biological behavior.[2] The principal characteristic of these tumors is that they are locally aggressive and show a high rate of recurrence. Separation of eccrine carcinoma has traditionally been according to their behavior into low grade and high grade malignant.[3] Proper identification of eccrine carcinoma is sometimes challenging due to the morphological similarity to other common tumors and the lack of consistent immunohistochemical markers. 

Etiology

Research has not uncovered a clear etiology.

Epidemiology

Eccrine carcinoma is an extremely rare cutaneous malignancy that accounts for less than 0.01% of diagnosed cutaneous malignancies[1]

Histopathology

Sweat gland tumors divide into eccrine, apocrine, mixed origin (eccrine and apocrine) and other un-classifiable sweat gland tumors. In real practice, most sweat gland tumors have both eccrine and apocrine components. Some even show complexity such as showing other lines of differentiation, namely follicular and/or sebaceous.[4] This differentiation is possibly due to the close embryological relationship between apocrine glands and pilosebaceous units.  Histopathologies closely associated with eccrine carcinoma include hidradenocarcinoma, spiradenocarcinoma, and porocarcinoma.[2] 

Some relatively important and common types of eccrine carcinoma include porocarcinomas, syringoid carcinoma, ductal carcinomas, adenoid cystic carcinomas, and mucinous carcinomas.[5] Porocarcinomas are characteristically solid neoplastic lobular masses with cystic changes and necrosis. Two types of atypical cells are present in porocarcinomas: eosinophilic and clear cells. These tumor cells are usually positive for cytokeratin and PAS. Syringoid carcinoma shows a mix of tubules, keratinizing cystic structures, solid islands, cellular cords, and desmoplastic stroma, resembling syringomas to some extent. Ductal carcinomas characteristically demonstrate by the presence of tubular structures mixed with variable amounts of cellular cords. The degree of differentiation range from well to poorly differentiated. Tumor cells are positive for PAS, D-PAS and, cytokeratins.[6] Adenoid cystic carcinomas are morphologically composed of basaloid and monomorphous cells; moderately atypical with hyperchromatic nuclei and inconspicuous cytoplasm. Tumor cells typically arrange in cribriform masses, islands, and tubular structures. Mucinous carcinomas are morphologically composed of cells, arranged in solid islands, cribriform masses, tubules, and small nests embedded in large mucin pools.[5]

Immunohistochemistry and molecular genetics play only a minor role in the diagnosis of sweat gland tumors, however, can be useful in excluding other possible entities. One relevant entity to exclude is cutaneous metastases from visceral primary adenocarcinomas.[3] When pathological complexity is evident, and the pathologist cannot fit the case to any established category, they should render a descriptive diagnosis of benign/malignant tumor with sweat gland differentiation.[7]

History and Physical

EC present as a brown, bluish, erythematous nodule, papule or ulcerative lesion. Lesions can present anywhere in the body. However, the lower extremities (35%), head and neck (24%), and upper extremities (14%) are common regions.[2][8]

Evaluation

The test of choice in the diagnosis of eccrine carcinoma is skin biopsy. The biopsy will show infiltrative, moderately to poorly differentiated neoplasm in a nested to the trabecular pattern. Nuclei are relatively uniform with notably prominent nucleoli. The specific morphology depends on the distinct eccrine carcinoma entity. Relatively common types of eccrine carcinoma include porocarcinomas, syringoid carcinoma, ductal carcinomas, adenoid cystic carcinomas, and mucinous carcinomas.[5] Immunohistochemistry (IHC) may be helpful in some cases; however, it is inconsistent. Markers that can support an EC diagnosis include carcinoembryonic antigen (CEA), epithelial membrane antigen (EMA), estrogen receptors (ER), progesterone receptors (PR), cytokeratin 7 (CK-7), and pancytokeratins.[9][10]

Treatment / Management

Wide surgical excision with the goal of clear margins is the treatment of choice of EC.[4] Chemotherapy and radiation therapy have been used for metastatic lesions.[1] Because EC is an infrequent entity, no randomized control trials exist that examine the management options.

Differential Diagnosis

  • Basal cell carcinoma (BCC): BCC is the most common malignancy of skin and approximately constitutes up to 80% of all skin cancers. BCC occurs more commonly in the sun-exposed skin. The most common presentation of BCC is in the form of a papule or a nodule. Morphologically BCC appears as basaloid cells with scant cytoplasm and elongated hyperchromatic nuclei. Positive stains that aid in confirming the diagnosis include: BerEP4, 34betaE12, MNF 116, p53, BCL2, and p63. Negative stains include EMA, CEA, involucrin, and CK20.
  • Squamous cell carcinoma (SCC): SCC is the second most malignancy of skin. SCC is graded based on the degree of differentiation and keratinization into well, moderately and poorly differentiated. Common presentations of SCC include a thin plaque or erythematous scaly papule. Positive stains that aid in confirming the diagnosis include: 34betaE12, AE1/AE3, CK5/6, EMA, and p63. Negative stains include CAM5.2, BerEP4, S100, and SMA.
  • Amelanotic melanoma: Amelanotic melanoma is a variant of melanoma that presents as white or reddish lesions. Similar to other common skin malignancies amelanotic melanoma is more common in the sun-exposed skin. Similar to malignant melanoma, Amelanotic melanoma prognosis is determined by two important factors that include lesion thickness and lesion degree of invasion.
  • Seborrheic keratosis: These are benign skin lesion affecting primarily adult patients. The lesion presents as a sharply demarcated pigmented greasy lesion that elevates above the surface of the skin. On microscopic examination, the lesion appears as an acanthotic proliferations of small cuboidal keratinocytes without any evidence of cytological atypia.
  • Cutaneous lymphoma.
  • Verruca vulgaris.
  • Metastatic carcinoma: Skin metastases from breast, lung or kidney carcinoma should be kept in the differential of eccrine carcinoma.

Staging

Eccrine carcinoma pathologically stages (pTNM) as follows:

Primary Tumor (pT)

  • pTX: Primary tumor not assessable
  • pT0: No evidence of primary tumor
  • pTis: Carcinoma in situ
  • pT1: Tumor 2 cm or less in the largest dimension
    • pT1a: Limited to the dermis or 2 mm or less in thickness
    • pT1b: Limited to the dermis and more than 2 mm in thickness, but not more than 6 mm in thickness
    • pT1c: Invading the subcutis and/or more than 6 mm in thickness
  • pT2: Tumor greater than 2 cm but not more than 5 cm in its greatest dimension
    • pT2a: Limited to the dermis or 2 mm or less in thickness
    • pT2b: Limited to the dermis and more than 2 mm in thickness but not more than 6 mm in thickness
    • pT2c: Invading the subcutis and/or more than 6 mm in thickness
  • pT3: Tumor over 5 cm in its greatest dimension
    • pT3a: Limited to the dermis or 2 mm or less in thickness
    • pT3b: Limited to the dermis and more than 2 mm in thickness, but not more than 6 mm in thickness
    • pT3c: Invading the subcutis and/or more than 6 mm in thickness
  • pT4: Tumor invades the deep extradermal tissue (e.g., cartilage, skeletal muscle, bone)
    • pT4a: 6 mm or less in thickness
    • pT4b: More than 6 mm in thickness

Regional Lymph Nodes (pN)

  • pNX: Regional lymph nodes not
  • assessablepN0: No regional lymph node metastasis
  • pN1: Regional lymph node metastasis

Distant Metastasis (pM)

  • pMX: Presence of distant metastasis not
  • assessablepM1: Distant metastasis

Prognosis

Metastatic disease shows poor prognosis. The relative mortality rate is 80%, and the 10-year disease overall survival rate is 9%.[2]

Complications

Eccrine carcinoma complications include metastases and/or adverse effects related to surgical intervention.

Deterrence and Patient Education

Patients should receive education regarding the prognosis and the possible adverse side effects of surgical intervention before beginning treatment.

Enhancing Healthcare Team Outcomes

Eccrine carcinoma is an extremely rare cutaneous malignancy. The prognosis is overall favorable in localized early lesions, however an unfavorable prognosis in metastatic lesions.[1] Eccrine carcinoma needs a multidisciplinary management approach with a medical oncologist, surgeon, dermatologist, dermatopathologist, pharmacist, and oncology nurse all playing a role in the management of the condition and working collaboratively to bring about optimal patient treatment and outcomes. [Level V]


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Cancer, An Overview of Eccrine Carcinoma - References

References

Sidiropoulos M,Sade S,Al-Habeeb A,Ghazarian D, Syringoid eccrine carcinoma: a clinicopathological and immunohistochemical study of four cases. Journal of clinical pathology. 2011 Sep;     [PubMed]
Urso C,Bondi R,Paglierani M,Salvadori A,Anichini C,Giannini A, Carcinomas of sweat glands: report of 60 cases. Archives of pathology     [PubMed]
van der Horst MPJ,Brenn T, Update on Malignant Sweat Gland Tumors. Surgical pathology clinics. 2017 Jun;     [PubMed]
Cardoso JC,Calonje E, Malignant sweat gland tumours: an update. Histopathology. 2015 Nov;     [PubMed]
Larson K,Babiker HM,Kovoor A,Liau J,Eldersveld J,Elquza E, Oral Capecitabine Achieves Response in Metastatic Eccrine Carcinoma. Case reports in oncological medicine. 2018;     [PubMed]
Moy RL,Rivkin JE,Lee H,Brooks WS,Zitelli JA, Syringoid eccrine carcinoma. Journal of the American Academy of Dermatology. 1991 May     [PubMed]
Abedi SM,Yu R,Salama S,Alowami S, Syringoid eccrine carcinoma. Cutis. 2015 Sep     [PubMed]
Idrissi Serhrouchni K,Harmouch T,Chbani L,El Fatemi H,Sekal M,Hammas N,Soughi M,Benchat L,Amarti A, Eccrine carcinoma : a rare cutaneous neoplasm. Diagnostic pathology. 2013 Feb 4     [PubMed]
Swanson PE,Cherwitz DL,Neumann MP,Wick MR, Eccrine sweat gland carcinoma: an histologic and immunohistochemical study of 32 cases. Journal of cutaneous pathology. 1987 Apr     [PubMed]
Ohnishi T,Kaneko S,Egi M,Takizawa H,Watanabe S, Syringoid eccrine carcinoma: report of a case with immunohistochemical analysis of cytokeratin expression. The American Journal of dermatopathology. 2002 Oct     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Surgery-Urologic. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Surgery-Urologic, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Surgery-Urologic, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Surgery-Urologic. When it is time for the Surgery-Urologic board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Surgery-Urologic.